Eucommia polysaccharide composition for treating osteoporosis and application thereof

By using Eucommia ulmoide polysaccharide 10KD and 100KD compositions with specific monosaccharide composition ratios, the adverse reactions and side effects in the treatment of postmenopausal osteoporosis were solved, and the effect of improving bone density and reducing inflammation and oxidative stress was achieved, providing A safe and effective treatment option.

CN118416092BActive Publication Date: 2024-11-22HUBEI RENYUANTANG PHARM BIOENGINEERING CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410594737.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-14
Publication Date
2024-11-22
Estimated Expiration
2044-05-14

AI Technical Summary

Technical Problem

The existing postmenopausal osteoporosis treatment drugs have adverse effects and side effects, which limit patient compliance and treatment effectiveness, and lack safe and effective treatment options.

Method used

Provide a composition composed of Eucommia ulmoide polysaccharide 10KD and Eucommia ulmoide polysaccharide 100KD. Through specific monosaccharide composition ratios and preparation methods, it is used to improve bone density, reduce bone conversion indicators, reduce inflammatory factors and oxidative stress, as a new osteoporosis treatment drugs.

Benefits of technology

Eucommia polysaccharide composition significantly improves bone density, reduces bone conversion indicators, inflammatory factors and oxidative stress, and provides a safe and effective therapeutic option that outperforms the side effects and effects of existing chemical drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118416092B_ABST
    Figure CN118416092B_ABST
Patent Text Reader

Abstract

The invention provides a eucommia polysaccharide composition for treating osteoporosis and its application, belonging to the technical field of osteoporosis treatment. The eucommia polysaccharide composition is composed of two eucommia polysaccharides, namely eucommia polysaccharide 10KD and eucommia polysaccharide 100KD, and their monosaccharide composition ratio has a specific distribution. Eucommia polysaccharide 10KD contains glucose, galactose, rhamnose, fucose, arabinose, galacturonic acid, glucuronic acid and mannuronic acid, while the monosaccharide composition of eucommia polysaccharide 100KD contains glucose, galactose, arabinose, rhamnose, fucose, galacturonic acid and glucuronic acid. The difference in this monosaccharide composition and ratio leads to differences in the functions of the two, so that the therapeutic effect after the two are used in combination is better than the therapeutic effect of a single polysaccharide or other combinations, showing a synergistic effect, thereby achieving the treatment of postmenopausal osteoporosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of osteoporosis treatment, and in particular relates to an eucommia polysaccharide composition for treating osteoporosis and an application thereof. Background Art

[0002] Osteoporosis is a chronic disease characterized by decreased bone density and degeneration of bone microstructure, which makes the patient's bones fragile and easily fractured by slight external force or ordinary impact in daily activities. This condition not only seriously affects the patient's mobility, but also may cause long-term pain, functional impairment and even disability, greatly reducing the patient's quality of life and social participation.

[0003] Postmenopausal osteoporosis is a more common form of osteoporosis, especially in middle-aged and elderly women. Currently, the incidence of postmenopausal osteoporosis is on the rise worldwide, which is related to the aging of the population and the extension of female life expectancy. As women enter menopause, the level of estrogen in the body begins to gradually decline, and this change has a profound impact on bone health. Estrogen plays an important role in maintaining bone density and inhibiting bone resorption. The decrease in its level will lead to decreased bone mass and destruction of bone microstructure, and ultimately increase bone brittleness. Therefore, the prevention and treatment of postmenopausal osteoporosis is particularly important.

[0004] In modern medicine, there are an increasing number of drug options for the treatment of postmenopausal osteoporosis, including but not limited to calcitonin, bisphosphonates, parathyroid hormone analogs, and estrogen replacement therapy. These drugs play an important role in increasing bone density and reducing the risk of fractures. However, long-term use of these drugs may bring a series of adverse reactions, including but not limited to increasing the risk of cardiovascular and cerebrovascular diseases, causing gastrointestinal discomfort, neurological problems, and may promote the development or spread of certain cancers. The presence of these side effects limits patient compliance and treatment effects, and also poses a potential threat to the patient's overall health. Therefore, new therapeutic drugs need to be developed to effectively treat patients with postmenopausal osteoporosis and reduce the occurrence of treatment side effects. Summary of the invention

[0005] The purpose of the present invention is to provide a Eucommia polysaccharide composition for treating osteoporosis and application thereof, so as to achieve pharmacological treatment of postmenopausal osteoporosis.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] First, the present invention provides an application of an eucommia polysaccharide composition in preparing a drug for treating osteoporosis, characterized in that the eucommia polysaccharide composition consists of eucommia polysaccharide 10KD and eucommia polysaccharide 100KD;

[0008] The monosaccharide composition of the Eucommia ulmoides polysaccharide 10KD is 35.45% glucose, 18.53% galactose, 7.31% rhamnose, 2.77% fucose, 2.08% arabinose, 10.23% galacturonic acid, 13.23% glucuronic acid and 10.40% mannuronic acid;

[0009] The monosaccharide composition of the Eucommia ulmoides polysaccharide 100KD is 33.16% glucose, 22.78% galactose, 17.83% arabinose, 12.41% rhamnose, 0.89% fucose, 3.44% galacturonic acid and 9.49% glucuronic acid.

[0010] Preferably, in the Eucommia ulmoides polysaccharide composition, the mass ratio of Eucommia ulmoides polysaccharide 10KD to Eucommia ulmoides polysaccharide 100KD is 1:1.

[0011] Preferably, the osteoporosis is postmenopausal osteoporosis.

[0012] Preferably, the Eucommia ulmoides polysaccharide 10KD and the Eucommia ulmoides polysaccharide 100KD are prepared according to the following preparation method:

[0013] (1) extracting the dried and crushed Eucommia ulmoides raw material by reflux extraction with 95% ethanol, and collecting the Eucommia ulmoides residue to remove the oil component in the Eucommia ulmoides raw material;

[0014] (2) Add the Eucommia ulmoides residue to 20 times the amount of distilled water, heat in a water bath at 80°C for 3 hours, cool to room temperature, collect the supernatant, repeat the operation twice, combine the supernatants obtained from the three extractions, and obtain a preliminary extract of Eucommia ulmoides polysaccharide;

[0015] (3) The primary extract of Eucommia ulmoides polysaccharide was concentrated to 20% of the original volume, 4 times the volume of ethanol solution was added, and the mixture was allowed to stand at 4°C overnight. The precipitate was collected by centrifugation to obtain crude Eucommia ulmoides polysaccharide;

[0016] (4) Dissolve the crude polysaccharide of Eucommia ulmoides in distilled water to obtain a 0.1% (W / V) crude polysaccharide solution a, mix the crude polysaccharide solution and Sevag reagent in a ratio of 5:1, and repeat the operation 9 times to obtain a crude polysaccharide solution b;

[0017] (5) The crude polysaccharide solution b and the macroporous resin are mixed in a volume ratio of 4:1, and after sufficient shaking, the macroporous resin is separated by suction filtration to obtain the Eucommia polysaccharide solution;

[0018] (6) Separating the Eucommia polysaccharide solution by ultrafiltration technology, filtering with a 10 kDa filter membrane, discarding the filtrate, passing the retentate through a 50 kDa filter membrane, the filtrate is a 10KD solution of Eucommia polysaccharides with a molecular weight of 10-50 kDa, and passing the retentate through a 100 kDa filter membrane, the retentate is a 100KD solution of Eucommia polysaccharides above 100 kDa;

[0019] (7) The Eucommia polysaccharide 10KD solution and 100KD solution were freeze-dried to obtain EUP-10KD and EUP-100KD.

[0020] Preferably, the concentration of the Eucommia polysaccharide composition in the medicine is 20 mg / mL, and the excipient of the medicine is physiological saline.

[0021] Preferably, the drug is administered orally.

[0022] Secondly, the present invention provides an application of an eucommia polysaccharide composition in the preparation of a drug for inhibiting inflammatory response and oxidative stress in patients with postmenopausal osteoporosis, wherein the eucommia polysaccharide composition consists of eucommia polysaccharide 10KD and eucommia polysaccharide 100KD;

[0023] The monosaccharide composition of the Eucommia ulmoides polysaccharide 10KD is 35.45% glucose, 18.53% galactose, 7.31% rhamnose, 2.77% fucose, 2.08% arabinose, 10.23% galacturonic acid, 13.23% glucuronic acid and 10.40% mannuronic acid;

[0024] The monosaccharide composition of the Eucommia ulmoides polysaccharide 100KD is 33.16% glucose, 22.78% galactose, 17.83% arabinose, 12.41% rhamnose, 0.89% fucose, 3.44% galacturonic acid and 9.49% glucuronic acid.

[0025] Preferably, in the Eucommia ulmoides polysaccharide composition, the mass ratio of Eucommia ulmoides polysaccharide 10KD to Eucommia ulmoides polysaccharide 100KD is 1:1.

[0026] Preferably, the Eucommia ulmoides polysaccharide 10KD and the Eucommia ulmoides polysaccharide 100KD are prepared by the above-mentioned preparation method.

[0027] Preferably, the concentration of the Eucommia polysaccharide composition in the medicine is 20 mg / mL, and the excipient of the medicine is physiological saline.

[0028] Preferably, the drug is administered orally.

[0029] Secondly, the present invention provides an application of an eucommia polysaccharide composition in the preparation of a drug for increasing the bone density of patients with postmenopausal osteoporosis, characterized in that the eucommia polysaccharide composition consists of eucommia polysaccharide 10KD and eucommia polysaccharide 100KD;

[0030] The monosaccharide composition of the Eucommia ulmoides polysaccharide 10KD is 35.45% glucose, 18.53% galactose, 7.31% rhamnose, 2.77% fucose, 2.08% arabinose, 10.23% galacturonic acid, 13.23% glucuronic acid and 10.40% mannuronic acid;

[0031] The monosaccharide composition of the Eucommia ulmoides polysaccharide 100KD is 33.16% glucose, 22.78% galactose, 17.83% arabinose, 12.41% rhamnose, 0.89% fucose, 3.44% galacturonic acid and 9.49% glucuronic acid.

[0032] Preferably, in the Eucommia ulmoides polysaccharide composition, the mass ratio of Eucommia ulmoides polysaccharide 10KD to Eucommia ulmoides polysaccharide 100KD is 1:1.

[0033] Preferably, the Eucommia ulmoides polysaccharide 10KD and the Eucommia ulmoides polysaccharide 100KD are prepared by the above-mentioned preparation method.

[0034] Preferably, the concentration of the Eucommia polysaccharide composition in the medicine is 20 mg / mL, and the excipient of the medicine is physiological saline.

[0035] Preferably, the drug is administered orally.

[0036] Secondly, the present invention provides a drug for treating postmenopausal osteoporosis, wherein the core active ingredient of the drug is a eucommia polysaccharide composition, the auxiliary material of the drug is normal saline, and the eucommia polysaccharide composition consists of eucommia polysaccharide 10KD and eucommia polysaccharide 100KD;

[0037] The monosaccharide composition of the Eucommia ulmoides polysaccharide 10KD is 35.45% glucose, 18.53% galactose, 7.31% rhamnose, 2.77% fucose, 2.08% arabinose, 10.23% galacturonic acid, 13.23% glucuronic acid and 10.40% mannuronic acid;

[0038] The monosaccharide composition of the Eucommia ulmoides polysaccharide 100KD is 33.16% glucose, 22.78% galactose, 17.83% arabinose, 12.41% rhamnose, 0.89% fucose, 3.44% galacturonic acid and 9.49% glucuronic acid.

[0039] Preferably, in every 1 mL of the drug, the content of the eucommia polysaccharide composition is 20 mg, and in the eucommia polysaccharide composition, the mass ratio of eucommia polysaccharide 10KD to eucommia polysaccharide 100KD is 1:1.

[0040] The beneficial effects of the present invention are:

[0041] The present invention provides a new eucommia polysaccharide composition, in which eucommia polysaccharide 10KD and eucommia polysaccharide 100KD respectively have specific monosaccharide composition ratios and unique biological activity, so that the combination of eucommia polysaccharide 10KD and polysaccharide 100KD produces a synergistic therapeutic effect on a specific type of osteoporosis, postmenopausal osteoporosis, which helps to improve the patient's bone density, reduce bone turnover indicators, and reduce inflammatory factors and oxidative stress. Compared with existing chemical drugs, polysaccharide drugs of natural origin have better safety and lower side effects.

[0042] In general, the Eucommia polysaccharide composition of the present invention shows significant therapeutic effect and potential clinical application value in the treatment of postmenopausal osteoporosis, providing patients with a new and safe treatment option. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 This is the result diagram of monosaccharide composition of Eucommia ulmoides polysaccharide detected by ion chromatography;

[0044] Figure 2 This is the morphological result of Eucommia ulmoides polysaccharide detected by SEM;

[0045] Figure 3 To investigate the effect of Eucommia ulmoides polysaccharide treatment on bone density in mice;

[0046] Figure 4 The effect of Eucommia ulmoides polysaccharide treatment on alkaline phosphatase in mouse serum;

[0047] Figure 5 The effect of Eucommia polysaccharide treatment on osteocalcin in mouse serum. DETAILED DESCRIPTION

[0048] In the following section, we will explain the present invention in more detail through specific implementation strategies. It should be noted that the embodiments provided are intended to clearly illustrate the concepts and applications of the present invention and are not intended to limit the scope of application of the present invention. These embodiments should be regarded as the basis for further exploration and improvement by those skilled in the art, rather than as a limitation to the possibilities of the present invention.

[0049] The experimental procedures mentioned in the examples, unless otherwise explicitly stated, generally adopt the standard methods recognized in the industry. These methods are based on the techniques or conditions described in the literature of the relevant field, or follow the instructions in the product instructions. As for the materials and reagents used in the examples, unless otherwise specified, they are generally standard products available through commercial channels.

[0050] Example 1: This example prepares eucommia polysaccharides of different molecular weights

[0051] (1) 500 g of dried and crushed Eucommia ulmoides raw material was reflux extracted three times with 3 L of 95% ethanol, and the Eucommia ulmoides residue was collected to remove the oil component in the Eucommia ulmoides raw material;

[0052] (2) Add the obtained Eucommia ulmoides residue to 10 L of distilled water, heat in a water bath at 80° C. for 3 hours, cool to room temperature, collect the supernatant, repeat this operation 2 more times, combine the supernatants obtained from the 3 extractions, and obtain a preliminary extract of Eucommia ulmoides polysaccharide;

[0053] (3) Using a rotary evaporator, the preliminary extract of Eucommia ulmoides polysaccharide was concentrated to 20% of the original volume, 4 times the volume of ethanol solution was added, and the mixture was allowed to stand at 4°C overnight. The precipitate was collected by centrifugation to obtain crude Eucommia ulmoides polysaccharide;

[0054] (4) Dissolve the crude polysaccharide of Eucommia ulmoides in distilled water to obtain a 0.1% (W / V) crude polysaccharide solution a, mix the crude polysaccharide solution with Sevag reagent (chloroform: n-butanol = 4:1) in a ratio of 5:1, and repeat this operation 9 times to effectively remove the protein, thereby obtaining a crude polysaccharide solution b;

[0055] (5) The crude polysaccharide solution b and the macroporous resin were mixed in a volume ratio of 4:1, placed in a constant temperature oscillator and oscillated for 16 h, and the macroporous resin was separated by suction filtration to obtain an eucommia polysaccharide solution;

[0056] (6) Separating the Eucommia polysaccharide solution by ultrafiltration technology, filtering with a 10 kDa filter membrane, discarding the filtrate, passing the retentate through a 50 kDa filter membrane, the filtrate being the Eucommia polysaccharide 10KD solution (EUP-10KD solution) with a molecular weight of 10-50 kDa, passing the retentate through a 100 kDa filter membrane, the filtrate being the Eucommia polysaccharide 50KD solution (EUP-50KD solution) with a molecular weight of 50-100 kDa, and the retentate being the Eucommia polysaccharide 100KD solution (EUP-100KD solution) with a molecular weight of more than 100 kDa;

[0057] (7) Freeze-drying the Eucommia polysaccharide 10KD, 50KD and 100KD solutions to obtain EUP-10KD, EUP-50KD and EUP-100KD

[0058] Example 2: Ion chromatography in this example detects the monosaccharide composition of polysaccharides

[0059] Fucose, rhamnose, arabinose, galactose, glucose, xylose, mannose, fructose, galacturonic acid glucose, glucuronic acid, and mannuronic acid were used as monosaccharide standards.

[0060] (1) Weigh 5 mg of the sample, add 1 mL of 2 M trifluoroacetic acid (TFA, 3 mol / L) and heat at 121 °C for 3 hours;

[0061] (2) Then, dry under a nitrogen stream. Subsequently, add 50 mL of water and vortex mix.

[0062] (3) After filtration, the supernatant was analyzed using HPIC equipped with a Dionex™ CarboPac™ PA20 (150*3.0 mm, 10 μm) liquid chromatography column and an electrochemical detector;

[0063] (4) 0.1 M NaOH, 0.1 M NaOH, and 0.2 M NaAc were used as mobile phases, the flow rate was set to 0.5 mL / min, the injection volume was 5 uL, and the column temperature was 30 °C;

[0064] (5) Treat the monosaccharide standard solution in the same way as above and calculate the molar mass based on the molar mass of the monosaccharide;

[0065] (6) The monosaccharide compositions of polysaccharide samples of different molecular weights of P. chebula were analyzed by HPLC, and their compositions were determined using IC and by matching the retention times in the chromatographic curves with those of monosaccharide standards.

[0066] The results are shown in Table 1 and Figure 1 As shown:

[0067] Table 1 Monosaccharide composition ratio of Eucommia ulmoides polysaccharides with different molecular weights

[0068]

[0069] From Table 1 and Figure 1 It can be seen that the main monosaccharide component of EUP-10KD is glucose (Glc, accounting for 35.45%), followed by galactose (Gal, accounting for 18.53%). In addition, it also contains a certain proportion of rhamnose (Rha, 7.31%), fucose (Fuc, 2.77%), arabinose (Ara, 2.08%), galacturonic acid (Gal-UA, 10.23%), glucuronic acid (Glc-UA, 13.23%) and mannuronic acid (Man-UA, 10.40%);

[0070] In EUP-50KD, glucose (Glc, 40.94%) and galactose (Gal, 18.32%) are also the main components, but the content of rhamnose (Rha, 18.10%) is significantly higher than that of EUP-10KD. This sample does not contain fucose (Fuc), galacturonic acid (Gal-UA) and mannuronic acid (Man-UA), but contains a higher proportion of glucuronic acid (Glc-UA, 18.08%) and arabinose (Ara, 4.56%);

[0071] In the monosaccharide composition of EUP-100KD, glucose (Glc, accounting for 33.16%) and galactose (Gal, accounting for 22.78%) are still the main components, but the content of arabinose (Ara, 17.83%) has increased significantly, exceeding the proportion in EUP-10KD and EUP-50KD. Rhamnose (Rha, 12.41%) and fucose (Fuc, 0.89%) also contribute. It also does not contain mannuronic acid (Man-UA), but contains a small amount of galacturonic acid (Gal-UA, 3.44%) and glucuronic acid (Glc-UA, 9.49%).

[0072] This indicates that there are great differences in the monosaccharide composition of Eucommia polysaccharides with different molecular weights, which will lead to differences in pharmacological activities.

[0073] Example 3: This example uses SEM to detect the morphology of polysaccharides

[0074] (1) The surface morphology of three different molecular weight polysaccharides from Rhizoma Cibotii were observed using a Hitachi S-3400N-II SEM system at an accelerating voltage of 20 kV.

[0075] (3) The sample was fixed on the sample holder with the help of double-sided carbon tape, and then sputtered with platinum powder using an ion sputtering coater. The results are as follows: Figure 2 shown.

[0076] from Figure 2 It can be seen that the SEM images show obvious differences in the surface morphology of the three different molecular weight Eucommia polysaccharides. The surface morphology of EUP-10KD shows a large number of irregular oval rough surface features, EUP-50KD presents a smooth flaky surface morphology, and EUP-100KD presents a more finely broken flaky surface morphology.

[0077] Example 4: This example constructs a mouse model of postmenopausal osteoporosis

[0078] A. Animal grouping and dosing regimen

[0079] Forty-two 6-week-old BALB / c mice were purchased and randomly divided into 7 groups after one week of adaptation feeding. They were blank group (normal saline), model group (normal saline), EUP-10KD group (EUP-10KD, 200 mg / Kg), EUP-50KD group (EUP-50KD, 200 mg / Kg), EUP-100KD group (EUP-100KD, 200 mg / Kg), EUP-10KD + EUP-50KD group (EUP-10KD : EUP-50KD =1 : 1 (g : g), 200 mg / Kg, EUP-10KD + EUP-100KD group (EUP-10KD : EUP-100KD =1 : 1 (g : g), 200 mg / Kg). Eucommia polysaccharide was prepared with normal saline, and the gavage volume was 10 mL / Kg, once a day. The blank group and the model group were gavaged with the same amount of normal saline every day for 14 days.

[0080] B. Establishment of postmenopausal osteoporosis model in mice

[0081] (1) Preoperative preparation: Patients should fast for 12 hours before oophorectomy. The operation should be performed in a sterile environment.

[0082] (2) Anesthesia: 10% chloral hydrate 0.5 mL / 100 g intraperitoneally, wait 3-5 min.

[0083] (3) Skin preparation: Remove the stray hair on both sides of the back of the mouse, place the mouse in a prone position on the operating table, and apply iodine to the surgical area for disinfection.

[0084] (4) A longitudinal incision of about 0.5 cm long was made on both sides of the mouse iliac crest, about 1 cm above the top, between the third and fourth lumbar vertebrae. The retroperitoneum was opened, the muscles were cut away from the blood vessels, and the white fat mass was gently peeled off. The dark red mulberry-shaped soybean-sized ovarian tissue was visible. The blank group underwent sham surgery, and only the fat tissue around the bilateral ovaries was cut off. The other 6 groups had bilateral ovaries removed.

[0085] (5) After gently peeling off the fat around the ovaries, the fallopian tubes and the accompanying ovarian arteries and veins connected to the ovaries can be seen. The fallopian tubes and the accompanying arteries and veins are ligated with 3-0 silk thread, the ovaries are removed, and pressure is applied to stop bleeding for 30 seconds. Excess fat can be trimmed, and the abdominal cavity is closed with 4-0 silk thread, and the skin is sutured. The skin is disinfected with alcohol.

[0086] (6) Repeat steps (3) and (4) to ligate and remove the other ovary, suture the muscles and skin, and disinfect with alcohol. After surgery, intramuscular injection of penicillin 0.02 mL / animal / day for 3 consecutive days. Start medication two weeks after surgery.

[0087] One hour after the last administration, serum was collected from the abdominal aorta of all mice and centrifuged. Mice were anesthetized by intraperitoneal injection of sodium barbital (10%, 0.5 mL / 100 g). After successful anesthesia, the bilateral femurs of the mice were removed, soaked in 4% paraformaldehyde, and sealed for storage.

[0088] Example 5: This example detects bone density in different animal groups

[0089] Bone density is divided into area bone density and volume bone density. In clinical practice, area bone density is usually used. Area bone density refers to the bone mineral content per unit area. The area bone density of the left femur of mice was measured on a digital DR dual-energy X-ray absorptiometry instrument at a speed of 1 mm / s using stored femurs. It is expressed in g / cm 2 To express the bone density (BMD) of mice, the results are as follows Figure 3 shown.

[0090] According to experimental data (such as Figure 3 As shown in the figure, it can be observed that there are significant differences in bone mineral density (BMD) between mice in different treatment groups. In the untreated model group mice, the BMD level was significantly lower than that in the control group, which simulates the typical pathological characteristics of osteoporosis, namely, decreased bone mineral density. However, the drug-treated mouse group showed a significant increase in BMD levels, which revealed the positive effect of drug treatment on improving osteoporosis symptoms.

[0091] It is particularly noteworthy that, with the same amount of polysaccharide drugs added, the group of mice treated with EUP-10KD and EUP-100KD showed the most significant increase in BMD levels, which not only surpassed the single drug treatment group, but also surpassed the effect of EUP-10KD and EUP-50KD combined. This finding suggests that the combined use of EUP-10KD and EUP-100KD may have a synergistic effect and can more effectively promote the recovery of bone density.

[0092] Example 6: This example detects bone turnover indicators in different animal groups

[0093] (1) Add the pre-coated bone-specific alkaline phosphatase capture antibody and bone-specific osteocalcin capture antibody into a 96-well plate, and set sample wells and specimen wells;

[0094] (2) Add the standard and experimental samples separately, then add the HRP-labeled detection antibody, and use an enzyme reader to detect the absorbance at a wavelength of 450 nm to calculate the levels of ALP and OC in the serum.

[0095] According to the experimental results, Figure 4 and Figure 5The results showed that the model group mice showed significant increases in two biochemical indicators, alkaline phosphatase (ALP) and osteocalcin (OC), which is consistent with the changes in typical biomarkers of postmenopausal osteoporosis. Increases in ALP and OC are usually associated with increased bone turnover, which is a key feature in the pathological process of postmenopausal osteoporosis.

[0096] After drug treatment of osteoporotic mice, a decrease in ALP and OC levels was observed in all treatment groups, indicating that drug treatment has a positive effect on slowing down the bone turnover process and reducing the activity of osteoporosis. Among all treatment groups, the group of mice treated with the combination of EUP-10KD and EUP-100KD showed the most significant decrease in ALP and OC levels, further proving that the combination of EUP-10KD and EUP-100KD has a synergistic therapeutic effect on postmenopausal osteoporosis.

[0097] Example 7: This example detects serum inflammatory factors in different animal groups

[0098] (1) Refer to the instructions of the ELISA kits for TNF-α and IL-6 to operate the sera from different animal groups;

[0099] (2) The levels of serum TNF-α and IL-6 were determined by measuring the absorbance at 450 nm using an enzyme-labeled instrument. The results are shown in Table 2.

[0100] Table 2 Determination of TNF-α and IL-6 levels in serum of mice in each group

[0101]

[0102] As can be seen from Table 2, based on the data comparison in Table 2, we can observe that compared with the blank control group, the level of inflammatory factors in the model group increased significantly, which is consistent with the pathological state of the ovariectomy-induced osteoporosis mouse model.

[0103] In the five experimental groups that received treatment, the levels of TNF-α and IL-6 in the mouse serum decreased compared with the model group, indicating that the treatment measures effectively reduced the inflammatory response. It is particularly noteworthy that the EUP-10KD + EUP-100KD combination treatment group showed the most significant effect in reducing the levels of these pro-inflammatory cytokines, and its therapeutic effect far exceeded that of other single or combination treatment groups.

[0104] Example 8: This example detects bone oxidative stress factors in different animal groups

[0105] (1) The femur was removed from the storage, homogenized in 0.9% saline to a homogenate (10%), and then centrifuged at 15,000 rpm in a centrifuge to obtain a clear supernatant;

[0106] (2) To evaluate the level of oxidative stress in femoral samples, the thiobarbituric acid reactive substances (TBARS) method was used to measure the level of oxidative stress in femoral samples. The reagent containing the unsaturated fatty acid oxidation products, aldehyde compounds, and the femoral supernatant samples to be tested were added to the biochemical kit;

[0107] (3) adding horseradish peroxidase (HRP) labeled reagent to the reaction system;

[0108] (4) After the reaction is fully completed, the absorbance of the reaction solution is measured at a wavelength of 450 nm using an enzyme reader (such as a microplate reader) and the level of TBARS is calculated. The results are shown in Table 3.

[0109] Table 3 Determination of bone oxidative stress factor TBARS in each group of mice

[0110]

[0111] By carefully analyzing the data provided in Table 3, we can observe an obvious phenomenon: all experimental groups except the blank group have increased TBARS levels. As a biomarker for assessing oxidative stress status, an increase in TBARS levels is usually associated with tissue damage and enhanced inflammatory response. This result shows that except for the blank group, mice in other groups experienced a certain degree of oxidative stress, which is consistent with the characteristics of the ovariectomy-induced osteoporosis model.

[0112] Further analysis showed that after drug intervention, TBARS levels in mice in all treatment groups decreased significantly, indicating that the treatment effectively alleviated the state of oxidative stress. Among these treatment groups, the combination of EUP-10KD and EUP-100KD was particularly outstanding in reducing TBARS levels, and its effect was better than other treatments alone or in combination. This finding strongly suggests that the combination of Eucommia polysaccharides EUP-10KD and EUP-100KD has a synergistic antioxidant effect, thereby combating the progression of osteoporosis.

[0113] In summary, the embodiments of the present invention systematically demonstrate the process of extracting polysaccharides from Eucommia ulmoides, the chemical composition and morphological characteristics of polysaccharides, and the therapeutic effect in the postmenopausal osteoporosis model. In particular, the combined use of EUP-10KD and EUP-100KD showed a synergistic effect in improving bone density, reducing bone turnover indicators, and reducing inflammatory factors and oxidative stress, indicating that it has potential application value in the treatment of osteoporosis.

Claims

1. Use of an eucommia polysaccharide composition in preparing a drug for treating osteoporosis, characterized in that: The eucommia polysaccharide composition consists of eucommia polysaccharide 10KD and eucommia polysaccharide 100KD; The Eucommia ulmoides polysaccharide 10KD and the Eucommia ulmoides polysaccharide 100KD are prepared according to the following preparation method: (1) extracting the dried and crushed Eucommia ulmoides raw material by reflux extraction with 95% ethanol, and collecting the Eucommia ulmoides residue to remove the oil component in the Eucommia ulmoides raw material; (2) Add the Eucommia ulmoides residue to 20 times the amount of distilled water, heat in a water bath at 80°C for 3 hours, cool to room temperature, collect the supernatant, repeat the operation twice, combine the supernatants obtained from the three extractions, and obtain a preliminary extract of Eucommia ulmoides polysaccharide; (3) The primary extract of Eucommia ulmoides polysaccharide was concentrated to 20% of the original volume, 4 times the volume of ethanol solution was added, and the mixture was allowed to stand at 4°C overnight. The precipitate was collected by centrifugation to obtain crude Eucommia ulmoides polysaccharide; (4) Dissolve the crude polysaccharide of Eucommia ulmoides in distilled water to obtain a 0.1% (W / V) crude polysaccharide solution a, mix the crude polysaccharide solution and Sevag reagent in a ratio of 5:1, and repeat the operation 9 times to obtain a crude polysaccharide solution b; (5) The crude polysaccharide solution b and the macroporous resin are mixed in a volume ratio of 4:1, and after sufficient shaking, the macroporous resin is separated by suction filtration to obtain the Eucommia polysaccharide solution; (6) Separating the Eucommia polysaccharide solution by ultrafiltration technology, filtering with a 10 kDa filter membrane, discarding the filtrate, passing the retentate through a 50 kDa filter membrane, the filtrate is a 10KD solution of Eucommia polysaccharides with a molecular weight of 10-50 kDa, and passing the retentate through a 100 kDa filter membrane, the retentate is a 100KD solution of Eucommia polysaccharides above 100 kDa; (7) freeze-drying the Eucommia polysaccharide 10KD solution and the Eucommia polysaccharide 100KD solution to obtain Eucommia polysaccharide 10KD and Eucommia polysaccharide 100KD; In the eucommia polysaccharide composition, the mass ratio of eucommia polysaccharide 10KD to eucommia polysaccharide 100KD is 1:

1.

2. The use of a Eucommia polysaccharide composition according to claim 1 in preparing a drug for treating osteoporosis, characterized in that: The osteoporosis is postmenopausal osteoporosis.

3. Use of an Eucommia polysaccharide composition in the preparation of a drug for inhibiting inflammatory response and oxidative stress in patients with postmenopausal osteoporosis, wherein: The eucommia polysaccharide composition consists of eucommia polysaccharide 10KD and eucommia polysaccharide 100KD; The Eucommia polysaccharide 10KD and the Eucommia polysaccharide 100KD are prepared by the preparation method described in claim 1; In the eucommia polysaccharide composition, the mass ratio of eucommia polysaccharide 10KD to eucommia polysaccharide 100KD is 1:

1.

4. Use of an eucommia polysaccharide composition in the preparation of a drug for increasing bone density in patients with postmenopausal osteoporosis, characterized in that: The eucommia polysaccharide composition consists of eucommia polysaccharide 10KD and eucommia polysaccharide 100KD; The Eucommia polysaccharide 10KD and the Eucommia polysaccharide 100KD are prepared by the preparation method described in claim 1; In the eucommia polysaccharide composition, the mass ratio of eucommia polysaccharide 10KD to eucommia polysaccharide 100KD is 1:

1.

5. A drug for treating postmenopausal osteoporosis, characterized in that: The core active ingredient of the drug is a eucommia polysaccharide composition, the auxiliary material of the drug is normal saline, and the eucommia polysaccharide composition consists of eucommia polysaccharide 10KD and eucommia polysaccharide 100KD; The Eucommia polysaccharide 10KD and the Eucommia polysaccharide 100KD are prepared by the preparation method described in claim 1; In every 1 mL of the medicine, the content of the eucommia polysaccharide composition is 20 mg. In the eucommia polysaccharide composition, the mass ratio of eucommia polysaccharide 10KD to eucommia polysaccharide 100KD is 1:1.